Overview

Intravenous Immunoglobulin for Unverricht-Lundborg Disease.

Status:
Unknown status
Trial end date:
2017-12-30
Target enrollment:
Participant gender:
Summary
Single patient randomized double blind trial to assess whether intravenous immunoglobulin can improve the clinical outcome of a case suffering from Unverricht-Lundborg disease.
Phase:
Phase 3
Details
Lead Sponsor:
Azienda Socio Sanitaria Territoriale di Mantova
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin